Base de dados : MEDLINE
Pesquisa : D02.455.426.559.847.638.183 [Categoria DeCS]
Referências encontradas : 769 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 77 ir para página                         

  1 / 769 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29238762
[Au] Autor:Ureña Torres PA; Bover J; Cohen-Solal M
[Ad] Endereço:Ramsay-Générale de Santé, Clinique du Landy, Department of Nephrology and Dialysis and Department of Renal Physiology, Necker Hospital, University of Paris Descartes, Paris, France. pablo.urena@wanadoo.fr.
[Ti] Título:Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.
[So] Source:Drugs Today (Barc);53(9):489-500, 2017 Sep.
[Is] ISSN:1699-3993
[Cp] País de publicação:Spain
[La] Idioma:eng
[Ab] Resumo:Chronic kidney disease is associated with mineral and bone disorders that are now considered as a syndrome. One of the major complications of this syndrome is secondary hyperparathyroidism (SHPT). SHPT increases bone turnover and the risk of fracture. SHPT is also associated with cardiovascular calcification and high mortality risk. The classical medical therapies of SHPT lack long-term efficacy and have undesirable effects on serum calcium and phosphate levels. Surgical parathyroidectomy is a radical therapeutic solution potentially exposing patients to a permanent state of hypoparathyroidism among other complications. Oral cinacalcet revolutionized the treatment of SHPT because of its great efficacy; however, more than one-third of patients do not respond appropriately to cinacalcet, mostly because of intolerance and lack of compliance. Intravenous etelcalcetide improves medical adherence and reduces pill burden. It is 10-15% superior than cinacalcet in controlling parathyroid hormone, but also leads to more frequent episodes of hypocalcemia.
[Mh] Termos MeSH primário: Hiperparatireoidismo Secundário/tratamento farmacológico
Peptídeos/administração & dosagem
Insuficiência Renal Crônica/complicações
[Mh] Termos MeSH secundário: Animais
Cloridrato de Cinacalcete/efeitos adversos
Cloridrato de Cinacalcete/uso terapêutico
Seres Humanos
Hiperparatireoidismo Secundário/etiologia
Adesão à Medicação
Hormônio Paratireóideo/metabolismo
Peptídeos/efeitos adversos
Peptídeos/farmacologia
Diálise Renal/métodos
Insuficiência Renal Crônica/terapia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AMG-416); 0 (Parathyroid Hormone); 0 (Peptides); 1K860WSG25 (Cinacalcet Hydrochloride)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE
[do] DOI:10.1358/dot.2017.53.9.2711938


  2 / 769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29192005
[Au] Autor:Srivastava T; Jafri S; Truog WE; Sebestyen VanSickle J; Manimtim WM; Alon US
[Ad] Endereço:Sections of Nephrology, Bone and Mineral Disorder Clinic, and.
[Ti] Título:Successful Reversal of Furosemide-Induced Secondary Hyperparathyroidism With Cinacalcet.
[So] Source:Pediatrics;140(6), 2017 Dec.
[Is] ISSN:1098-4275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Secondary hyperparathyroidism (SHPT) is a rare complication of furosemide therapy that can occur in patients treated with the loop diuretic for a long period of time. We report a 6-month-old 28-weeks premature infant treated chronically with furosemide for his bronchopulmonary dysplasia, who developed hypocalcemia and severe SHPT, adversely affecting his bones. Discontinuation of the loop diuretic and the addition of supplemental calcium and calcitriol only partially reversed the SHPT, bringing serum parathyroid hormone level down from 553 to 238 pg/mL. After introduction of the calcimimetic Cinacalcet, we observed a sustained normalization of parathyroid hormone concentration at 27 to 63 pg/mL and, with that correction, of all biochemical abnormalities and healing of the bone disease. No adverse effects were noted. We conclude that in cases of SHPT due to furosemide in which traditional treatment fails, there may be room to consider the addition of a calcimimetic agent.
[Mh] Termos MeSH primário: Calcimiméticos/uso terapêutico
Cálcio/sangue
Cloridrato de Cinacalcete/uso terapêutico
Furosemida/efeitos adversos
Hiperparatireoidismo Secundário/induzido quimicamente
[Mh] Termos MeSH secundário: Seres Humanos
Lactente
Imagem por Ressonância Magnética
Masculino
Hormônio Paratireóideo/sangue
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Calcimimetic Agents); 0 (Parathyroid Hormone); 1K860WSG25 (Cinacalcet Hydrochloride); 7LXU5N7ZO5 (Furosemide); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE


  3 / 769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28535231
[Au] Autor:Block GA; Chertow GM
[Ad] Endereço:Denver Nephrology, Denver, Colorado.
[Ti] Título:Dosing of Etelcalcetide vs Cinacalcet for Secondary Hyperparathyroidism-Reply.
[So] Source:JAMA;317(20):2132-2133, 2017 05 23.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Cloridrato de Cinacalcete
Hiperparatireoidismo Secundário
[Mh] Termos MeSH secundário: Cálcio
Seres Humanos
Falência Renal Crônica
Hormônio Paratireóideo
Diálise Renal
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Parathyroid Hormone); 1K860WSG25 (Cinacalcet Hydrochloride); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170606
[Lr] Data última revisão:
170606
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170524
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.4746


  4 / 769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28535228
[Au] Autor:Hai MTT; Guettier JM; Rosebraugh CJ
[Ad] Endereço:Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
[Ti] Título:Dosing of Etelcalcetide and Cinacalcet for Secondary Hyperparathyroidism.
[So] Source:JAMA;317(20):2132, 2017 05 23.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Cloridrato de Cinacalcete
Hiperparatireoidismo Secundário
[Mh] Termos MeSH secundário: Cálcio
Seres Humanos
Hiperparatireoidismo
Hormônio Paratireóideo
Diálise Renal
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Parathyroid Hormone); 1K860WSG25 (Cinacalcet Hydrochloride); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170606
[Lr] Data última revisão:
170606
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170524
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.4743


  5 / 769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28518414
[Au] Autor:Dulfer RR; Franssen GJH; Hesselink DA; Hoorn EJ; van Eijck CHJ; van Ginhoven TM
[Ad] Endereço:Department of Surgery, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
[Ti] Título:Systematic review of surgical and medical treatment for tertiary hyperparathyroidism.
[So] Source:Br J Surg;104(7):804-813, 2017 Jun.
[Is] ISSN:1365-2168
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A significant proportion of patients with chronic kidney disease and secondary hyperparathyroidism (HPT) remain hyperparathyroid after kidney transplantation, a state known as tertiary HPT. Without treatment, tertiary HPT can lead to diminished kidney allograft and patient survival. Parathyroidectomy was commonly performed to treat tertiary HPT until the introduction of the calcimimetic drug, cinacalcet. It is not known whether surgery or medical treatment is superior for tertiary HPT. METHODS: A systematic review was performed and medical literature databases were searched for studies on the treatment of tertiary HPT that were published after the approval of cinacalcet. RESULTS: A total of 1669 articles were identified, of which 47 were included in the review. Following subtotal and total parathyroidectomy, initial cure rates were 98·7 and 100 per cent respectively, but in 7·6 and 4 per cent of patients tertiary HPT recurred. After treatment with cinacalcet, 80·8 per cent of the patients achieved normocalcaemia. Owing to side-effects, 6·4 per cent of patients discontinued cinacalcet treatment. The literature regarding graft function and survival is limited; however, renal graft survival after surgical treatment appears comparable to that obtained with cinacalcet therapy. CONCLUSION: Side-effects and complications of both treatment modalities were mild and occurred in a minority of patients. Surgical treatment for tertiary HPT has higher cure rates than medical therapy.
[Mh] Termos MeSH primário: Calcimiméticos/uso terapêutico
Cloridrato de Cinacalcete/uso terapêutico
Hiperparatireoidismo Secundário/tratamento farmacológico
Hiperparatireoidismo Secundário/cirurgia
Transplante de Rim
Paratireoidectomia
Insuficiência Renal Crônica/cirurgia
[Mh] Termos MeSH secundário: Calcimiméticos/efeitos adversos
Cloridrato de Cinacalcete/efeitos adversos
Sobrevivência de Enxerto
Seres Humanos
Paratireoidectomia/efeitos adversos
Complicações Pós-Operatórias
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Calcimimetic Agents); 1K860WSG25 (Cinacalcet Hydrochloride)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170519
[St] Status:MEDLINE
[do] DOI:10.1002/bjs.10554


  6 / 769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28431775
[Au] Autor:Mostafa GAE; Al-Badr AA
[Ad] Endereço:College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
[Ti] Título:Cinacalcet Hydrochloride.
[So] Source:Profiles Drug Subst Excip Relat Methodol;42:1-90, 2017.
[Is] ISSN:1871-5125
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Cinacalcet hydrochloride is a calcimimetic agent that increases the sensitivity to the extracellular calcium of the calcium-sensing receptors of the parathyroid gland which regulates parathyroid hormone secretion. This comprehensive profile on cinacalcet hydrochloride starts with a description: nomenclature, formulae, chemical structure, elemental composition, and appearance. The uses and applications of the drug are included. The methods of preparation of cinacalcet hydrochloride are described and their respective schemes are outlined. The physical characterization of the drug is: ionization constant, solubility, X-ray powder diffraction (XRPD) pattern, crystal polymorphs, melting point, and differential scanning calorimetry. The spectral characteristics of the drug include: ultraviolet spectrum, vibrational spectrum, H and C nuclear magnetic resonance spectra, and the mass spectrum. The methods of analysis of the drug include: spectrophotometry, electrophoresis, fluorimetry, and high-performance liquid chromatography alone or with mass spectrometry. The stability of the drug in various media and storage conditions are reported. Biological studies on the drug include: the metabolism pharmacokinetics and pharmacodynamics. More than 100 references are listed at the end of the chapter.
[Mh] Termos MeSH primário: Calcimiméticos
Cloridrato de Cinacalcete
[Mh] Termos MeSH secundário: Calcimiméticos/química
Calcimiméticos/farmacologia
Calcimiméticos/uso terapêutico
Cloridrato de Cinacalcete/química
Cloridrato de Cinacalcete/farmacologia
Cloridrato de Cinacalcete/uso terapêutico
Seres Humanos
Hipercalcemia/tratamento farmacológico
Hiperparatireoidismo Secundário/tratamento farmacológico
Estrutura Molecular
Receptores de Detecção de Cálcio/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Calcimimetic Agents); 0 (Receptors, Calcium-Sensing); 1K860WSG25 (Cinacalcet Hydrochloride)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170423
[St] Status:MEDLINE


  7 / 769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28390426
[Au] Autor:Cheunsuchon B; Sritippayawan S
[Ad] Endereço:Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Road, Bangkok, 10700, Thailand. boonyarit.che@mahidol.ac.th.
[Ti] Título:Successful treatment of early allograft dysfunction with cinacalcet in a patient with nephrocalcinosis caused by severe hyperparathyroidism: a case report.
[So] Source:BMC Res Notes;10(1):153, 2017 Apr 08.
[Is] ISSN:1756-0500
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hyperparathyroidism is common in patients undergoing kidney transplantation. Occasionally, this condition can cause early allograft dysfunction by inducing calcium phosphate deposition in the allograft, which results in nephrocalcinosis. Although nephrocalcinosis occurs occasionally in kidney allografts, it has only rarely been reported in the literature. CASE PRESENTATION: Here, we present the case of a 58-year-old Thai woman with severe hyperparathyroidism who received a living-related kidney transplant from her 35-year-old son. Our patient developed allograft dysfunction on day 2 post-transplantation despite good functioning graft on day 1. Allograft biopsy showed extensive calcium phosphate deposition in distal tubules. She was treated with cinacalcet (a calcimimetic agent) and aluminum hydroxide. Allograft function was restored to normal within 1 week after transplantation with greatly reduced intact parathyroid hormone level. CONCLUSION: Hyperparathyroidism in early functioning allograft causes elevated calcium and phosphate concentration in distal tubules resulting in nephrocalcinosis. The massive calcium phosphate precipitation obstructs tubular lumens, which leads to acute tubular dysfunction. Treatment of nephrocalcinosis with cinacalcet is safe and may improve this condition by increasing serum phosphate and reducing serum calcium and intact parathyroid hormone.
[Mh] Termos MeSH primário: Cloridrato de Cinacalcete/uso terapêutico
Hiperparatireoidismo/complicações
Transplante de Rim/métodos
Nefrocalcinose/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Aloenxertos
Calcimiméticos/uso terapêutico
Fosfatos de Cálcio/metabolismo
Feminino
Seres Humanos
Túbulos Renais Distais/efeitos dos fármacos
Túbulos Renais Distais/metabolismo
Masculino
Meia-Idade
Nefrocalcinose/etiologia
Núcleo Familiar
Doadores de Tecidos
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Calcimimetic Agents); 0 (Calcium Phosphates); 1K860WSG25 (Cinacalcet Hydrochloride); 97Z1WI3NDX (calcium phosphate)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170424
[Lr] Data última revisão:
170424
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170410
[St] Status:MEDLINE
[do] DOI:10.1186/s13104-017-2477-0


  8 / 769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28336834
[Au] Autor:Hamano N; Fukagawa M
[Ad] Endereço:Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Japan.
[Ti] Título:[Parenteral calcimimetics for the treatment of secondary hyperparathyroidism.]
[So] Source:Clin Calcium;27(4):567-572, 2017.
[Is] ISSN:0917-5857
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:The oral calcimimetics, cinacalcet, is reported to be effective on secondary hyperparathyroidism resistant to classical treatment like phosphate binders or vitamin D receptor activator. The problem that gastrointestinal adverse events cause poor adherence, drug discontinuation, and insufficient dose escalation remains unsolved. The novel injectable calcimimetic, etelcalcetide, is recently developed and is expected to reduce such adverse events and improve the therapeutic effects on moderate to severe secondary hyperparathyroidism. Further studies are needed to demonstrate the potential benefits of etelcalcetide compared to cinacalcet.
[Mh] Termos MeSH primário: Calcimiméticos/uso terapêutico
Hiperparatireoidismo Secundário/tratamento farmacológico
[Mh] Termos MeSH secundário: Cloridrato de Cinacalcete/uso terapêutico
Ensaios Clínicos como Assunto
Seres Humanos
Falência Renal Crônica/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Calcimimetic Agents); 1K860WSG25 (Cinacalcet Hydrochloride)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170325
[St] Status:MEDLINE
[do] DOI:CliCa1704567572


  9 / 769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28277829
[Au] Autor:Hamano N; Komaba H; Fukagawa M
[Ad] Endereço:a Division of Nephrology , Tokai University School of Medicine , Isehara , Japan.
[Ti] Título:Etelcalcetide for the treatment of secondary hyperparathyroidism.
[So] Source:Expert Opin Pharmacother;18(5):529-534, 2017 Apr.
[Is] ISSN:1744-7666
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Calcium sensing receptor is an important target for the treatment of secondary hyperparathyroidism (SHPT). Etelcalcetide hydrochloride is a novel peptide calcimimetic agent that has a similar mechanism of action as cinacalcet hydrochloride. Clinical trials of etelcalcetide have been performed in the US, Europe, and Japan, and these trials demonstrated the safety and efficacy of etelcalcetide in dialysis patients. Etelcalcetide has recently been approved in Europe, the US and Japan. Areas covered: We review the development, pharmacokinetics, and clinical efficacy and safety of etelcalcetide for the treatment of SHPT in hemodialysis patients. We also summarize the clinical evidence regarding cinacalcet to forecast the potential clinical benefit of etelcalcetide. Expert opinion: Etelcalcetide is an injectable calcimimetic with a longer elimination half-life than cinacalcet. The injectable formulation improves adherence and reduces pill burden, while the frequency of gastrointestinal adverse events has been comparable between cinacalcet and etelcalcetide. The longer half-life of etelcalcetide reduces the fluctuation of biochemical markers of mineral and bone metabolism, but it remains to be determined whether such a sustained effect results in improved outcomes. Further studies are needed to determine the impact of etelcalcetide on clinical outcomes, particularly in comparison with the conventional calcimimetic cinacalcet.
[Mh] Termos MeSH primário: Calcimiméticos/uso terapêutico
Hiperparatireoidismo Secundário/tratamento farmacológico
Peptídeos/uso terapêutico
[Mh] Termos MeSH secundário: Cloridrato de Cinacalcete/uso terapêutico
Seres Humanos
Diálise Renal
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (AMG-416); 0 (Calcimimetic Agents); 0 (Peptides); 1K860WSG25 (Cinacalcet Hydrochloride)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170404
[Lr] Data última revisão:
170404
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170310
[St] Status:MEDLINE
[do] DOI:10.1080/14656566.2017.1303482


  10 / 769 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28104158
[Au] Autor:Nakai K; Fujii H; Ishimura T; Fujisawa M; Nishi S
[Ad] Endereço:Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan; Department of Nephrology and Kidney Center, Kakogawa East City Hospital, Kakogawa, Japan.
[Ti] Título:Incidence and Risk Factors of Persistent Hyperparathyroidism After Kidney Transplantation.
[So] Source:Transplant Proc;49(1):53-56, 2017 Jan - Feb.
[Is] ISSN:1873-2623
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Persistent hyperparathyroidism after kidney transplantation is related to graft function, but pre-transplantation risk factors of persistent hyperparathyroidism have not been evaluated in detail. We enrolled 86 patients who had undergone kidney transplantation between 2008 and 2014. Nine patients showed persistent hyperparathyroidism characterized by the following: 1) serum parathyroid hormone levels >65 pg/mL and serum calcium levels >10.5 mg/dL at 1 year after kidney transplantation; 2) parathyroidectomy after kidney transplantation; and 3) reintroduction of cinacalcet after kidney transplantation. Compared with other patients, these 9 patients had significantly longer duration of dialysis therapy (186 ± 74 mo vs 57 ± 78 mo) and more frequent treatment with cinacalcet during dialysis (89% vs 12%). Multivariate analysis showed that dialysis vintage, calcium phosphate products, and cinacalcet use before kidney transplantation were independent risk factors of persistent hyperparathyroidism after kidney transplantation. A receiver operating characteristic curve showed 72 months as the cutoff value of dialysis vintage and 55 as the cutoff value of calcium phosphate products. In conclusion, dialysis vintage >6 years, calcium phosphate products >55 (mg/dL) , and cinacalcet use before kidney transplantation are strong predictors of persistent hyperparathyroidism. High-risk patients should be evaluated for parathyroid enlargement, and parathyroidectomy must be considered before kidney transplantation.
[Mh] Termos MeSH primário: Hiperparatireoidismo/epidemiologia
Transplante de Rim/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Idoso
Calcimiméticos/uso terapêutico
Cálcio/sangue
Estudos de Casos e Controles
Cloridrato de Cinacalcete/uso terapêutico
Feminino
Seres Humanos
Hiperparatireoidismo/sangue
Hiperparatireoidismo/etiologia
Incidência
Masculino
Meia-Idade
Hormônio Paratireóideo/sangue
Paratireoidectomia
Período Pós-Operatório
Período Pré-Operatório
Diálise Renal/estatística & dados numéricos
Fatores de Risco
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Calcimimetic Agents); 0 (Parathyroid Hormone); 1K860WSG25 (Cinacalcet Hydrochloride); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170121
[St] Status:MEDLINE



página 1 de 77 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde